Upgrade to SI Premium - Free Trial

Neurocrine Biosciences (NBIX)

143.29 +1.98 (1.40%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/2/26)

Latest Headlines

Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome October 22, 2026 4:05 PM - PR NewsWire Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market October 21, 2026 10:40 AM - StreetInsider Neurocrine starts Phase 2 trial of NBI-567 for Alzheimer's disease October 20, 2026 8:30 AM - StreetInsider Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease October 20, 2026 8:30 AM - PR NewsWire Neurocrine presents real-world CAH patient journey data at nursing symposium October 16, 2026 8:30 AM - StreetInsider Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia October 16, 2026 8:30 AM - PR NewsWire Form SCHEDULE 13G/A NEUROCRINE BIOSCIENCES Filed by: JPMORGAN CHASE & CO October 15, 2026 1:40 PM - SEC Filing TD Cowen: 'Neurocrine Bio. (NBIX) Growth Story Appears Intact' October 14, 2026 9:19 AM - StreetInsider Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results October 12, 2026 4:01 PM - PR NewsWire Neurocrine Bio. (NBIX) PT Lowered to $150 at BMO Capital October 12, 2026 9:53 AM - StreetInsider Truist Securitas's Biotechnology Earnings Preview: 'INSM, BBIO, NBIX Most Levered to the Print' October 12, 2026 9:04 AM - StreetInsider Form 3 NEUROCRINE BIOSCIENCES For: Sep 28 Filed by: ROBERTS EIRY October 7, 2026 6:15 PM - SEC Filing Guggenheim Assumes Neurocrine Bio. (NBIX) at Buy October 5, 2026 4:09 PM - StreetInsider Neurocrine to present Vykat XR and PWS research at FPWR conference September 30, 2026 8:32 AM - StreetInsider Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Sympos September 30, 2026 8:30 AM - PR NewsWire Neurocrine Bio. (NBIX) PT Lowered to $214 at UBS, Buy Rating Maintained September 29, 2026 9:12 AM - StreetInsider Form 8-K NEUROCRINE BIOSCIENCES For: Sep 25 September 28, 2026 4:20 PM - SEC Filing Neurocrine Biosciences names returning CMO, parts ways with Keswani September 28, 2026 4:05 PM - StreetInsider Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer September 28, 2026 4:05 PM - PR NewsWire Neurocrine Bio. (NBIX) PT Lowered to $187 at RBC Capital September 21, 2026 8:24 AM - StreetInsider CCB Int'l Starts Neurocrine Bio. (NBIX) at Outperform September 18, 2026 6:10 AM - StreetInsider Form 4 NEUROCRINE BIOSCIENCES For: Sep 11 Filed by: Onyia Jude September 15, 2026 5:07 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: Sep 11 Filed by: Lippoldt Darin September 15, 2026 5:07 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: Sep 11 Filed by: Keswani Sanjay Chandru September 15, 2026 5:06 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: Sep 11 Filed by: GORMAN KEVIN CHARLES September 15, 2026 5:05 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: Sep 11 Filed by: Gano Kyle September 15, 2026 5:05 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: Sep 11 Filed by: Delaet Ingrid September 15, 2026 5:04 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: Sep 11 Filed by: Cooke Julie September 15, 2026 5:04 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: Sep 11 Filed by: Boyer David W. September 15, 2026 5:03 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: Sep 11 Filed by: BENEVICH ERIC September 15, 2026 5:03 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: Sep 11 Filed by: ABERNETHY MATT September 15, 2026 5:03 PM - SEC Filing Form 144 NEUROCRINE BIOSCIENCES Filed by: ABERNETHY MATT September 14, 2026 4:50 PM - SEC Filing Form 144 NEUROCRINE BIOSCIENCES Filed by: Boyer David W. September 14, 2026 4:40 PM - SEC Filing Neurocrine Bio. (NBIX) PT Raised to $183 at Morgan Stanley September 11, 2026 8:37 AM - StreetInsider Form 4 NEUROCRINE BIOSCIENCES For: Sep 09 Filed by: BENEVICH ERIC September 10, 2026 8:29 PM - SEC Filing RBC Capital on Neurocrine Bio. (NBIX): 'We like the setup and remain buyers' September 8, 2026 9:15 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $253 at Citi September 3, 2026 5:02 AM - StreetInsider Neurocrine Bio. (NBIX) PT Lowered to $182 at Morgan Stanley August 13, 2026 8:09 AM - StreetInsider Neurocrine's Ingrezza study shows quality-of-life gains in TD patients August 12, 2026 8:30 AM - StreetInsider Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living August 12, 2026 8:30 AM - PR NewsWire Neurocrine starts Phase 1 trial of obesity drug NBIP-1968 August 7, 2026 8:30 AM - StreetInsider Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist August 7, 2026 8:30 AM - PR NewsWire Form 4 NEUROCRINE BIOSCIENCES For: Aug 04 Filed by: Onyia Jude August 5, 2026 5:36 PM - SEC Filing Neurocrine Bio. (NBIX) PT Raised to $213 at Truist Securities August 3, 2026 7:06 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Neurocrine Bio. (NBIX) August 3, 2026 6:54 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $210 at Canaccord August 3, 2026 6:41 AM - StreetInsider Form S-8 NEUROCRINE BIOSCIENCES July 31, 2026 4:11 PM - SEC Filing Form 8-K/A NEUROCRINE BIOSCIENCES For: May 14 July 31, 2026 4:05 PM - SEC Filing Neurocrine Bio. (NBIX) PT Raised to $249 at Citi July 31, 2026 1:28 PM - StreetInsider Wells Fargo on Neurocrine Bio. (NBIX): 'Defending NBIX, We Would Be Buyers Here' July 31, 2026 11:35 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $215 at Cantor Fitzgerald July 31, 2026 10:22 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $220 at TD Cowen July 31, 2026 9:09 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $190 at BMO Capital July 31, 2026 8:58 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $210 at Piper Sandler July 31, 2026 8:35 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $198 at RBC Capital July 31, 2026 8:22 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $215 at Stifel July 31, 2026 8:09 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $196 at Morgan Stanley July 31, 2026 8:01 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $204 at Needham July 31, 2026 7:24 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $225 at Baird July 31, 2026 7:20 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $222 at Guggenheim July 31, 2026 6:59 AM - StreetInsider Form 10-Q NEUROCRINE BIOSCIENCES For: Jun 30 July 31, 2026 6:06 AM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: Jul 28 Filed by: Norwalk Leslie V July 30, 2026 5:29 PM - SEC Filing Neurocrine Biosciences (NBIX) Tops Q2 EPS by 127c ; Offers Guidance July 30, 2026 4:19 PM - StreetInsider Form 8-K NEUROCRINE BIOSCIENCES For: Jul 30 July 30, 2026 4:02 PM - SEC Filing Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results July 30, 2026 4:01 PM - PR NewsWire Form SCHEDULE 13G/A NEUROCRINE BIOSCIENCES Filed by: JPMORGAN CHASE & CO July 27, 2026 11:18 AM - SEC Filing Full Article List